Feelmore Labs, Inc.

Feelmore Labs was positioned at the intersection of health care, wellness, fitness, and consumer technology rather than within a narrowly defined software category. Its stated focus on medical and consumer devices suggests an attempt to bridge clinically oriented products and everyday wellness use cases. The company’s $20 million private equity round in 2019, followed by $4 million of debt financing in 2022, indicates access to institutional capital and a business model requiring meaningful investment in product development, manufacturing, or commercialization. However, the available profile does not identify a specific product, clinical indication, proprietary modality, customer segment, or distribution partnership. The company’s Brooklyn location and backing from M13, ARCH Venture Partners, and True Ventures provide context for its venture-backed positioning, but the listed closed operating status and absence of later commercial milestones indicate limited evidence of sustained market traction.

Feelmore Labs’ documented trajectory shows an early formation in 2016, institutional private equity financing of $20 million on Oct 1, 2019, and a subsequent $4 million debt financing on Mar 1, 2022. The financing sequence suggests an effort to progress from company formation and product development toward manufacturing or commercialization, particularly given the presence of a VP of Manufacturing since January 2019. Zen Chu has been identified as co-founder since October 2016, while Francois Kress is also listed as a founder. The available employee record contains only two current positions and does not provide a time series of headcount growth, hiring momentum, revenue, product releases, or market expansion. No later financing, launch, partnership, or award is documented after March 2022. Most importantly, the operating status is listed as closed, making the 2022 debt round the last visible inflection point rather than evidence of continuing expansion. Overall, the company advanced through significant capital formation but lacks documented post-financing growth indicators and appears to have ceased operations.